Check out the April 2022 EMA newsletter which features the latest updates on COVID-19 vaccines and antivirals, and recent regulatory approvals of drugs fighting cancer, diabetes, hematologic diseases, and HIV as well as drugs that target diseases of the immune, nervous, nephrology, and hormone system. In addition, it includes updates and revisions to EMA guidelines, as well as summaries of several public meetings held at EMA facilities.    

Read the newsletter below:


  • The material in these reviews is from various public open access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred